Discovery of a Novel Thienopyrimidine Derivative as a Potent Dual URAT1/GLUT9 Inhibitor

A 2026 dataset from figshare describes the development of 46 novel polycyclic pyrimidine derivatives for gout and hyperuricemia treatment. The dataset likely contains structural and experimental data for compounds, including lead compound F-5 and promising candidate 17. It was authored by Qian Yang and is licensed under CC-BY-NC-4.0.

Use Cases

• Analyzing compound efficacy based on IC50 values for URAT1 and GLUT9 inhibition
• Comparing pharmacokinetic profiles based on bioavailability (F) data in rats
• Evaluating safety profiles based on acute toxicity test results at high doses
• Studying structure-guided design outcomes from scaffold hopping techniques

Strengths

• Contains specific efficacy metrics, including IC50 values of 4.01 μM for URAT1 and 1.60 μM for GLUT9
• Includes pharmacokinetic data, such as a bioavailability (F) of 33.71% for compound 17
• Reports concrete safety results, showing no acute toxicity at 1000 mg/kg

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect experimental bias inherent to the specific research project

Provenance

Source

figshare

Collection Method

Scaffold hopping and structure-guided design from lead compound F-5

Freshness

Last updated 2026-05-06 16:08:11